Related Experiment Video
Updated: Sep 25, 2026

Investigation of Protein Recruitment to DNA Lesions Using 405 Nm Laser Micro-irradiation
Published on: March 20, 2018
ONO-1714 (Ono)
1William Harvey Research Institute, St Bartholomew's & the Royal London, School of Medicine & Dentistry, Charterhouse Square, London, EC1M 6BQ, UK. b.j.whittle@mds.qmw.ac.uk
Abstract:
Ono Pharmaceuticals is developing ONO-1714, a selective inducible NO synthase modulator, for the potential treatment of sepsis and hypotension. By March 1999, ONO-1714 had entered phase I trials [354023]. By June 2002, a phase II trial in hypotension during dialysis was ongoing in Japan and clinical pharmacology trials were underway in the UK [446138]. In August 1999, Lehmann Brothers gave ONO-1714 a 10% probability of reaching the market with an expected launch in 2004. Sales were expected to peak at 50 million US dollars in 2012 [349228].
Insights
Ono Pharmaceuticals is developing ONO-1714, a selective inducible nitric oxide synthase modulator, for sepsis and hypotension. Clinical trials were ongoing as of June 2002, with a projected market launch in 2004.
Area of Science:
- Pharmacology
- Clinical Trials
- Drug Development
Background:
- Ono Pharmaceuticals is developing ONO-1714.
- ONO-1714 is a selective inducible nitric oxide synthase (iNOS) modulator.
- The drug is intended for the potential treatment of sepsis and hypotension.
Purpose of the Study:
- To assess the safety and efficacy of ONO-1714 in clinical trials.
- To evaluate ONO-1714 for the treatment of hypotension during dialysis.
- To conduct clinical pharmacology trials for ONO-1714.
Main Methods:
- Phase I trials initiated by March 1999.
- Phase II trial for hypotension during dialysis ongoing in Japan by June 2002.
- Clinical pharmacology trials conducted in the UK.
Main Results:
- ONO-1714 entered Phase I trials in March 1999.
- A Phase II trial for hypotension during dialysis was in progress by June 2002.
- Clinical pharmacology trials were underway in the UK.
Conclusions:
- ONO-1714 is under investigation for sepsis and hypotension.
- Clinical development progressed through Phase II trials.
- Market launch was projected for 2004 with significant sales expectations.
Related Concept Videos
Nuclear Overhauser Enhancement (NOE)
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Acids, Bases and Neutralization Reactions
Noble Gases
The elements in group 18 are noble gases (helium, neon, argon, krypton, xenon, and radon). They earned the name “noble” because they were assumed to be nonreactive since they have filled valence shells. In 1962, Dr. Neil Bartlett at the University of British Columbia proved this assumption to be false.
Precipitation Reactions
Titration Calculations: Weak Acid - Strong Base
For the titration of 25.00 mL of 0.100 M CH3CO2H with 0.100 M NaOH, the reaction can be represented as:
